Intellia Therapeutics, Inc. (NTLA) Stock Rating Reaffirmed by Jefferies Group LLC
Intellia Therapeutics, Inc. (NASDAQ:NTLA)‘s stock had its “buy” rating restated by Jefferies Group LLC in a research report issued to clients and investors on Tuesday. They presently have a $36.00 target price on the stock. Jefferies Group LLC’s target price points to a potential upside of 21.13% from the company’s current price.
Several other equities research analysts also recently weighed in on the stock. Wedbush reaffirmed an “ourperform” rating and issued a $25.00 price objective (down previously from $29.00) on shares of Intellia Therapeutics in a report on Wednesday, September 27th. ValuEngine raised shares of Intellia Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, September 22nd. Barclays PLC assumed coverage on shares of Intellia Therapeutics in a report on Wednesday, September 6th. They issued an “overweight” rating and a $29.00 price objective for the company. Chardan Capital downgraded shares of Intellia Therapeutics from a “buy” rating to a “neutral” rating and set a $20.00 price objective for the company. in a report on Tuesday, August 29th. Finally, Cann reissued a “hold” rating on shares of Intellia Therapeutics in a report on Tuesday, August 1st. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $26.80.
Intellia Therapeutics (NASDAQ NTLA) traded down 3.5017% during trading on Tuesday, reaching $28.6793. 254,320 shares of the company’s stock traded hands. The stock’s market capitalization is $1.04 billion. The company has a 50-day moving average of $24.33 and a 200 day moving average of $24.33. Intellia Therapeutics has a 12 month low of $10.83 and a 12 month high of $31.90.
Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, August 3rd. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.03). The company had revenue of $5.90 million during the quarter, compared to analyst estimates of $5.83 million. Intellia Therapeutics had a negative return on equity of 22.70% and a negative net margin of 204.48%. The firm’s quarterly revenue was up 40.5% compared to the same quarter last year. On average, equities research analysts expect that Intellia Therapeutics will post ($1.78) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This news story was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://www.watchlistnews.com/intellia-therapeutics-inc-ntla-stock-rating-reaffirmed-by-jefferies-group-llc/1610824.html.
In other Intellia Therapeutics news, major shareholder Venture Fund Ix L.P. Atlas sold 150,000 shares of the company’s stock in a transaction dated Tuesday, July 11th. The shares were sold at an average price of $16.24, for a total value of $2,436,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 12.80% of the stock is currently owned by corporate insiders.
Hedge funds have recently bought and sold shares of the business. SG Americas Securities LLC purchased a new stake in Intellia Therapeutics during the second quarter valued at about $101,000. IHT Wealth Management LLC purchased a new stake in Intellia Therapeutics during the first quarter valued at about $117,000. Bank of Montreal Can lifted its stake in Intellia Therapeutics by 1,031.7% during the second quarter. Bank of Montreal Can now owns 7,922 shares of the company’s stock valued at $127,000 after buying an additional 7,222 shares in the last quarter. Nationwide Fund Advisors lifted its stake in Intellia Therapeutics by 117.7% during the second quarter. Nationwide Fund Advisors now owns 8,048 shares of the company’s stock valued at $129,000 after buying an additional 4,351 shares in the last quarter. Finally, Nisa Investment Advisors LLC purchased a new stake in Intellia Therapeutics during the second quarter valued at about $134,000. 46.52% of the stock is owned by institutional investors.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Receive News & Ratings for Intellia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.